Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Genfit   /   Koers Genfit 2016

Aandeel Genfit PSE:GNFT.FR, FR0004163111

Laatste koers (eur) Verschil Volume
4,060   +0,040   (+1,00%) Dagrange 3,945 - 4,110 137.854   Gem. (3M) 312,7K

Koers Genfit 2016

Volgen
159 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 | Laatste | Omlaag ↓
  1. harrysnel 6 december 2016 09:00
    "Pharmaceutical companies including Sanofi, Novartis AG and Shire Plc may be interested in Genfit, people familiar with the matter said last year..."

    Gilead is ook weleens genoemd als bedrijf dat geïnteresseerd zou kunnen zijn in samenwerking/overname Genfit.. Zie bv dit artikel (is een persoonlijke visie van auteur dus voor wat het waard is):
    www.nashbiotechs.com/nash-biotech-ana...
  10. greenways 9 december 2016 13:10
    Er zit iig weer wat leven in het aandeel, hopen dat de koersdoelen die afgegeven zijn, niet het eindstation wordt, want dan heb ik een paar jaar vergooit met dit aandeel, met de wetenschap,dik in de plus te hebben gestaan, om bij 34 misschien net be te staan.
    We gaan het wel weer meemaken, succes de aankomende tijd.
  13. [verwijderd] 17 december 2016 17:59
    enkele mooie artikels over genfit:

    Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?

    www.fool.com/investing/2016/12/17/cou...

    5 Stocks That Could Make You Rich

    www.nasdaq.com/article/5-stocks-that-...

    en dan is er het nieuwsbericht van genfit zelf nog van deze week:

    www.genfit.com/wp-content/uploads/201...
  14. [verwijderd] 18 december 2016 11:15
    quote:

    JOVRO schreef op 17 december 2016 17:59:

    enkele mooie artikels over genfit:

    Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?

    www.fool.com/investing/2016/12/17/cou...

    5 Stocks That Could Make You Rich

    www.nasdaq.com/article/5-stocks-that-...

    en dan is er het nieuwsbericht van genfit zelf nog van deze week:

    www.genfit.com/wp-content/uploads/201...
    Goed werk Jovro, AB.
  15. sp1946 20 december 2016 09:27
    Nu Genfit nog.

    Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan
    - Conference Call and Webcast Presentation at 5:30 p.m. ET Today -
    - Continuing Initial Focus on NASH Cirrhosis with Parallel Development in NASH Fibrosis -
    - Full Funding in Position for Remaining Development of Emricasan -
    SAN DIEGO, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis, Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis.
    Conatus is eligible to receive significant payments if certain development, regulatory and commercial milestones are met. Furthermore, Conatus is eligible to receive tiered double digit royalties on emricasan single agent sales and tiered single to double digit royalties on sales of combination products containing emricasan. Conatus has the option to co-commercialize emricasan in the United States, including combination therapies, on a cost-sharing and revenue-sharing basis in lieu of U.S. royalties and with reduced ex-U.S. royalties. Conatus retains limited rights to develop other pan-caspase inhibitors.
  16. [verwijderd] 20 december 2016 19:00
    quote:

    sp1946 schreef op 20 december 2016 09:27:

    Nu Genfit nog.

    Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan
    - Conference Call and Webcast Presentation at 5:30 p.m. ET Today -
    - Continuing Initial Focus on NASH Cirrhosis with Parallel Development in NASH Fibrosis -
    - Full Funding in Position for Remaining Development of Emricasan -
    SAN DIEGO, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis, Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis.
    Conatus is eligible to receive significant payments if certain development, regulatory and commercial milestones are met. Furthermore, Conatus is eligible to receive tiered double digit royalties on emricasan single agent sales and tiered single to double digit royalties on sales of combination products containing emricasan. Conatus has the option to co-commercialize emricasan in the United States, including combination therapies, on a cost-sharing and revenue-sharing basis in lieu of U.S. royalties and with reduced ex-U.S. royalties. Conatus retains limited rights to develop other pan-caspase inhibitors.

    Is wel onverwacht ,eerdere presentaties waren niet echt super
  17. [verwijderd] 21 december 2016 14:36
    scrip.pharmamedtechbi.com/SC097811/Ge...

    Executive Summary

    Lack of pruritus and a positive cardiometabolic profile could give elafibranor an advantage as it competes with Intercept’s Ocaliva to be the first drug therapy to market in NASH. The French biotech also is working on a biomarker algorithm to optimize patient selection.
  19. sp1946 5 januari 2017 17:03
    en weer een stapje verder in de NASH.

    J&J has grabbed an option to buy Bird Rock Bio and its experimental NASH drug candidate, the CB1-targeting antibody namacizumab, if the pharma giant likes what it sees in an ongoing Phase I study.
    La Jolla, CA-based Bird Rock, which changed its name from RuiYi, is going after the Cannabinoid receptor 1, which J&J also believes has potential for treating diabetic kidney disease. No terms were given for their option and collaboration, which topped J&J’s latest batch of deals from its global business development team.
159 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee